Proteinase specificity of a proteinaceous inhibitor of subtilisin (SSI; Streptomyces subtilisin inhibitor) can be altered so as to strongly inhibit trypsin simply by replacing P1 methionine with lysine (with or without concomitant change of the P4 residue) through site-directed nutagenesis. Now the crystal structure of one such engineered SSI (P1 methionine converted to lysine and P4 methionine converted to glycine) complexed with bovine trypsin has been solved at 2.6 A resolution and refined to a crystallographic R factor of 0.173. Comparing this structure with the previously established structure of the native SSI complexed with subtilisin BPN', it was found that (i) P1 lysine of the mutant SSI is accommodated in the Si pocket of trypsin as usual, and (ii) upon complex formation, considerable conformation change occurs to the reactive site loop of the mutant SSI. Thus, in this case, flexibility of the reactive site loop seems important for successfully changing the proteinase specificity through mere replacement of the P1 residue.
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Hypervariability of reactive site amino acid residues during evolution of proteinaceous inhibitors of serine proteinases is one of the major mysteries of protein evolution (1) . In contrast, in most other biologically active proteins, the replacement of active site residues, even by closely related ones, leads to a complete loss of activity or a dramatic decrease in activity. Among the reactive site residues of serine proteinase inhibitors, the P1 residue [after the Schechter and Berger notation (2) ] most significantly affects proteinase specificity. For example, strong trypsin inhibitors most frequently have lysine or arginine at P1, while strong chymotrypsin inhibitors have tyrosine, phenylalanine, leucine, or methionine at P1 (1) . Thus, the hypervariability of P1 residues inevitably causes a frequent change in proteinase specificity during gradual evolution of the same series of inhibitor proteins. It has been known that one can also invoke such a dramatic change in specificity by semisynthetic replacement of the P1 residue (3, 4) or by recombinant DNA techniques. Thus, the replacement of P1 methionine in a,-antitrypsin (a potent inhibitor of neutrophil elastase) with arginine converted the inhibitor into an efficient thrombin inhibitor (5) . The replacement of P1 methionine in a proteinaceous inhibitor [SSI; Streptomyces subtilisin inhibitor (6) , an almost exclusive subtilisin inhibitor] with lysine or arginine converted it to a potent inhibitor of both trypsin and subtilisin BPN' (7) .
Despite rather abundant observations of the dramatic change in proteinase specificity, however, the structural mechanisms of these phenomena are by no means obvious considering that (i) very good complementarity between the inhibitor and proteinase surfaces is almost always found in the crystallographically established structures of the inhibitor-proteinase complexes (8) (9) (10) (11) (12) (13) (14) and thus such good complementarity seems essential for the tight binding (15) , and yet (ii) the surface geometry of the active sites of proteinases is considerably varied even among enzymes of the trypsin family, much less between enzymes of the trypsin family and those of the subtilisin family having a completely different polypeptide chain folding. In this respect, the chance to compare the three-dimensional structure of a proteinaceous inhibitor complexed with its natural target proteinase and that of a variant of the inhibitor complexed with a distinct target enzyme has long been awaited. Here we report the crystal structure of an engineered SSI, in which P1 methionine and P4 methionine were genetically converted to lysine and glycine, respectively, complexed with bovine trypsin. Comparing this structure with the previously established structure of the native SSI complexed with subtilisin BPN' (16, 17) , many intriguing points as to the structural mechanisms of the change in proteinase specificity have emerged.
SSI is one of the few well-characterized (for a detailed review, see ref. 6) microbial protein proteinase inhibitors and is a stable dimer (I2) composed of two identical subunits, each of Mr 11,500 (18) . It strongly inhibits a microbial serine proteinase subtilisin BPN' (E), (K; 10-11 M) forming an E2-2 complex. SSI virtually does not inhibit trypsin (Ki 10-4 M; see ref. 19 for a review). The crystal structure of free SSI was solved (20) and refined at 2.05 A resolution (Y.T. and Y.M., unpublished data). The crystal structure of the SSIsubtilisin complex was also solved (16, 20) and refined at 1.8 A resolution (17) . Compared with other similar complexes containing serine proteinases of the trypsin family (8) (9) (10) (11) (12) (13) (14) 21) , the SSI-subtilisin complex is unique in several respects (16) : (i) In addition to the usual intermolecular antiparallel P-sheet interaction involving P1-P3 residues of the inhibitor, there is another antiparallel p-sheet formed between P4-P6 residues and a previously unnoticed chain segment [the "S4-6 site" (16) ] of subtilisin. (ii) Unlike various trypsin inhibitors, the P4-P9 residues of SSI are very flexible in the free state (22) and they undergo extensive rigidification and transconformation upon complex formation. The SSI gene has been cloned (23) and the expression system has been established (24) . Genetic conversion of P1 Met-73 to lysine (or arginine but no other amino acid residues) proved to convert SSI into a potent inhibitor of both trypsin (Ki = 4.4 x 10-9 M) and subtilisin BPN' (K; = 6 x 10-11 M) (25) ITo whom reprint requests should be addressed.
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subtilisin BPN', K-10-11 M) (26) , providing the best candidate for isolation of the complex with trypsin. Hereafter the (Met-73 to lysine, Met-70 to glycine) double mutant of SSI is referred to simply as "mutant SSI."
MATERIALS AND METHODS
Crystallization and Data Colection. Site-directed mutagenesis, DNA construction, and purification of the mutant SSI were performed as described (25) . Bovine trypsin was purchased from Worthington and was used without further purification. The method of complex formation is similar to that described (27) . Bovine trypsin and mutant SSI were dissolved separately in 0.05 M phosphate buffer (pH 7.2). The enzyme solution was added to the inhibitor solution in a 2:1.2 ratio (mol/mol) and the mixture was stirred gently at 370C for 30 min. For isolation of the complex, the reaction mixture was applied to a Biogel P-200 column previously equilibrated with 0.05 M phosphate buffer (pH 7. One asymmetric unit contains half the complex molecule (E-I). Hereafter, the mutant SSI-bovine trypsin complex is referred to simply as "SSI-trypsin complex." For x-ray data collection at =15'C, a macromolecule-oriented Weissenberg camera (28) installed at the synchrotron radiation source at the National Laboratory for High Energy Physics (Tsukuba) was used. The wavelength was set to 1.04 A. The single exceptionally large crystal mentioned above was used with the c axis as the rotation axis. The data sets recorded on a pack of Fuji imaging plate were processed as described (17) . The Rsym (l hu7,jl) -Ijj/11h(I)) was 6.3% for 23,106 observations up to 2.6 A resolution, I > 2a (I), which were reduced to 7579 independent reflections.
Structure Determination and Refinement. The structure was determined by the molecular replacement method (29) making use of (i) the known structure of bovine trypsin in the bovine pancreatic trypsin inhibitor (BPTI)-trypsin complex (21) 4. complex (Fig. 2) . The corresponding whole views of the two complex molecules are shown in Fig. 3 . The intermolecular contacts found in the SSI-trypsin complex are summarized in Table 1 . There are a total of 145 contacts of <4.0 A between the inhibitor and the enzyme. This is comparable to the corresponding numbers-126 found in the BPTI-trypsin complex (21) and 143 found in the SSI-subtilisin complex (16) [see tables 8.1(a) and -(b) of ref. 6 for counting details]-showing that the extent of loss of "accessible surface area" (35) upon complex formation is roughly the same among the three complexes.
Of the two separate antiparallel p-sheet interactions present in the SSI-subtilisin complex (16), the second one, involving the P4-P6 residues of the inhibitor, does not exist, reflecting the fact that the required S4-6 site is lacking in trypsin (16) . Even the first P-sheet interaction involving the P1-P3 residues is only poorly preserved, the only remaining hydrogen-bond being between P3 and S3 (see Table 1 ). Inspecting the location of the S1-S3 segment shown in Fig.  2 , the reason for the poorer interaction is easily seen: in the SSI-trypsin complex, the S1-S3 segment of the enzyme is considerably more distant from the P1-P3 segment of the inhibitor, making direct P1-Si interactions impossible. As for the contacts involving the secondary contact region (see legend to Fig. 1 ), the Q4 (Ser-981) and Q3 (Asn-99I) residues are in direct contact with trypsin. In particular, the O8, of Asn-991 forms a hydrogen bond with Ne1 of (see Table 1 ). Thus, as in the case of the SSI-subtilisin complex (17) , the secondary contact region contributes to intermolecular interaction in addition to its obvious role as a supporting device for the primary contact region. The P1 residue (Lys-73I) of mutant SSI is accommodated in the Si pocket with the hydrogen-bond distances from NE to three enzymatic atoms, carbonyl 0 (Ser-190), Or (Ser -FIG. 3 . The a-carbon chains of (i) the mutant SSI-bovine trypsin complex and (ii) the wild SSI-subtilisin BPN' complex colored and superimposed as in Fig. 2. 190), and 082 (Asp-189), being 2.95, 2.84, and 2.56 A, respectively. A similar scheme was found in the BPTItrypsin complex (21) and in the pancreatic secretory trypsin inhibitor-trypsinogen complex (10 as in the BPTI-trypsin complex (21), pancreatic secretory trypsin inhibitor-trypsinogen complex (10) , and ovomucoid inhibitor from turkey domain 3-Streptomyces griseus protease B complex (12) .
Conformation Changes in Trypsin and SSI on Complex Formation. We first compared the highly refined structure of trypsin in the BPTI-trypsin complex (21) with that of trypsin in the present complex. A global least-squares superposition ofthe two a-carbon chains gave a rms deviation of0.77 A. Six a-carbons deviate in position by >1.5 A: residues 25-26, 29, 147-148, and 174. All ofthem are on the exposed loops. These sites are localized and there seems to be no significant global conformation change upon complex formation.
The crystal structure of free SSI in a trigonal crystal form has recently been refined at 2.05 A resolution to an R factor of 0.194 (Y.T. and Y.M., unpublished data). Initial global least-squares superposition of the a-carbon chain of free SSI A from 08 to Gln-192 Ne
For the meaning of primary and secondary contact regions (P and Q notation) see Fig. 1 . upon that of mutant SSI in the present complex gave a rms deviation of 0.81 A. Then we realized that the structurally most conserved region of the SSI subunit resided in the core of the P-sheet, the .81-, 12-, and X4-strands. A second leastsquares superposition based on the 20 a-carbons belonging to this region gave a rms deviation of 0.4 A (Fig. 4) . Most conspicuous deviations are seen around the scissile bond (the reactive site) and along the flexible loop (see Fig. 1 ). These conformation changes seem to propagate through the a2-helix down to the C-terminal segment as indicated by the solid arrows in Fig. 1 Still, even the simpler requirements for tight and stable binding to the target enzymes appear not necessarily easy to fulfill. Since strong (noncovalent) interactions are most probably largely dependent on good complementarity of the surface geometries of the two component molecules (15, 35) , the surface geometries of relevant target proteinases must be more or less similar for an easy switch in proteinase specificity to occur. This would be relatively easily fulfilled if the switch is within proteinases of the trypsin family, since they are evolutionarily and structurally closely related to each other. For a switch to evolutionarily unrelated proteinases of the subtilisin family, however, a certain degree of flexibility in either one or both sides of the interacting molecules will have to be present. In the case of SSI, the flexible loop seems to play such a role. It remains to be seen whether or not such an easy and broad specificity change can occur for an inhibitor having no remarkable flexible parts.
Moreover, in some cases, the site remote from the reactive site can hamper such a broad specificity change. It has been known through extensive computer simulation studies (27) Fig. 1 ). These conformation changes on complex formation seem to propagate through the a2-helix and the C-terminal region, as indicated by the solid arrows in Fig. 1 .
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